Search

everythinglearnresearchcommunity

for

Search:↓

Using RU58841 twice daily for 6 months led to noticeable hair improvement. Consistency and finding a quality source are key.

The user saw no hair regrowth after six months using minoxidil, daily dermarolling, and vitamin D3. Many suggest adding finasteride or dutasteride for better results.

A user shared progress pictures showing significant hair regrowth after using 1mg finasteride and weekly microneedling for about 2.5 to 3 months. The user reported no side effects and maintained good health and mood.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.

A user reports positive results after 6 months using a topical finasteride/minoxidil spray and a hair and nail health vitamin for hair loss. They were initially skeptical but now are satisfied with their hair appearing to age gracefully.

The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.

The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.

The user is very satisfied with their hair transplant results after six months, using finasteride, minoxidil, and ketoconazole shampoo. They praise Dr. Anuj and consider future touch-ups for a small untouched crown area.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The user reported 4 months of using 0.5mg finasteride and 6 months of microneedling, Nizoral, and topical melatonin. They saw improvement on the left side but no improvement on the right side and are hesitant to start minoxidil.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

The user has seen positive results after over six months using 0.05% topical finasteride, 5% minoxidil, 50mg/ml RU58841, weekly needling, and twice-weekly ketoconazole shampoo for hair loss. They express gratitude for the support from an online community and are open to questions about their treatment.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.

The user shared their 6-month progress using finasteride and minoxidil for hair loss, noting improvements and reduced shedding. They decreased their minoxidil dosage from 10% to 5% and no longer need biotin, with no side effects from finasteride.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

The user experienced almost no improvement in hair loss after 3 months using microneedling, RU58841, sulforaphane, finasteride, and dutasteride, especially after stopping minoxidil. They believe minoxidil is more effective than RU58841.

User reports 6-month progress using Fin, Min, Nizoral, and Dermaroll for hair loss. Others comment on visible improvement and suggest waiting up to 2 years for full effects.

The user has been using finasteride for 6 months, experiencing hair regrowth at the hairline but thinning at the top and back. They are considering adding minoxidil to their routine to address the thinning and are concerned about potential shedding.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

The user experienced significant hair improvement using 1mg finasteride daily without side effects. They are advised to continue treatment to maintain results and consider cost-effective purchasing options.

A user on finasteride for 8 months shared bloodwork results showing increased testosterone and estradiol levels, with concerns about high LH. Responses advised monitoring for symptoms but noted levels are within reference ranges.

Increasing IGF-1 may help hair growth, but it could also increase hair loss in people with high testosterone. Treatments discussed include l-arginine, glutamine, vanadium, Deer Antler Velvet, ATP, Cocarboxylase, l-carnitine, and Mk677.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.